IMA ImageneBio, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1835579 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-0.2%
TTM EPS YoY83.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-32.3%
ROA-28.6%
ROIC (approx.)-98.2%
Asset turnover—
Leverage & solvency
Liabilities / assets10.1%
Debt / equity0.00x
Current ratio16.17x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.94x
Accruals ratio-1.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $800,000 | $3.50M | $9.16M | $15.62M | $30.98M |
| R&D expense | $28.52M | $32.11M | $59.65M | $64.32M | $47.11M |
| SG&A expense | $20.73M | $8.39M | $24.93M | $22.20M | $18.02M |
| Operating income | -$48.45M | -$37.00M | -$75.42M | -$70.90M | -$34.14M |
| Pretax income | -$45.70M | -$36.55M | -$68.33M | -$68.77M | — |
| Income tax | -$350,000 | $13,000 | -$162,000 | $0 | $0 |
| Net income | -$45.35M | -$36.57M | -$68.17M | -$68.77M | -$34.12M |
| EBITDA | -$48.05M | -$35.90M | -$74.40M | -$70.15M | -$33.59M |
| EPS (basic) | -9.64 | -22.10 | -1.63 | -1.90 | -1.22 |
| EPS (diluted) | -9.64 | -22.10 | -1.63 | -1.90 | -1.22 |
| Weighted avg. shares (diluted) | — | 48.26M | 41.74M | 36.19M | 27.98M |
| Balance sheet | |||||
| Cash & equivalents | $94.53M | $12.12M | $15.32M | $60.79M | $233.09M |
| Short-term investments | $40.82M | $0 | $55.57M | $97.03M | — |
| Current assets | $140.29M | $12.47M | $178.66M | $160.01M | $236.52M |
| PP&E, net | $0 | $8,000 | $2.33M | $3.21M | $2.44M |
| Total assets | $152.98M | $15.92M | $192.09M | $172.26M | $247.88M |
| Current liabilities | $11.23M | $17.21M | $14.21M | $21.50M | $27.19M |
| Short-term debt | $0 | $7.50M | — | — | — |
| Total liabilities | $19.84M | $17.45M | $22.34M | $25.29M | $40.00M |
| Shareholders' equity | $133.14M | -$160.56M | -$126.11M | $146.97M | $207.88M |
| Shares outstanding | — | 48.26M | 48.26M | 36.26M | 35.98M |
| Cash flow statement | |||||
| Operating cash flow | -$47.84M | -$21.32M | -$79.74M | -$74.11M | -$60.25M |
| Capital expenditure | — | — | $414,000 | $1.43M | $1.76M |
| Free cash flow | — | — | -$80.16M | -$75.54M | -$62.01M |
| Investing cash flow | -$5.81M | $11.12M | $64.14M | -$99.28M | -$1.76M |
| Financing cash flow | $135.47M | $6.91M | $75.98M | $1.09M | $131.74M |
| Depreciation & amortization | $400,000 | $1.10M | $1.02M | $751,000 | $544,000 |
| Stock-based compensation | $15.39M | $0 | $7.63M | $7.53M | $5.18M |
| Share buybacks | — | — | $663,000 | — | — |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.